The specificity of our covalent inhibitor of PfCLK3 over human kinases, demonstrated through kinase profiling and binding assays, underscores the potential for selective targeting of the parasite while potentially minimising off-target effects. Moreover, the exquisite selectivity index of the lead compound, chloroacetamide 4, for parasites over human cells highlights its promise as a therapeutic candidate with a large therapeutic window.